Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Myron Jacobs

Pulmonary Disease Saint Louis, MO Medical Doctor

NPI 1255322731 CMS profile 283965

11133 Dunn Rd, Suite 2335, Saint Louis, MO 63136

Open in the dashboard

General payments

$8,474

505 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Myron Jacobs of Saint Louis, MO is reported in the CMS Open Payments database as having received $8,474 across 505 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $110 4
2024 General $409 19
2023 General $608 31
2022 General $2,026 113
2021 General $1,432 96
2020 General $1,612 101
2019 General $2,278 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Myron Jacobs
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Myron Jacobs were reported at $110. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Myron Jacobs Pulmonary Disease median Middle half National median
2019 $2,278 $377 $109–$1,340 $163
2020 $1,612 $230 $56–$907 $114
2021 $1,432 $269 $68–$1,072 $132
2022 $2,026 $390 $100–$1,457 $149
2023 $608 $419 $114–$1,659 $160
2024 $409 $476 $123–$1,818 $164
2025 $110 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,316 126 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $1,090 61 payments
  3. Actelion Pharmaceuticals US, Inc. $945 42 payments
  4. AstraZeneca Pharmaceuticals LP $943 61 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $483 28 payments
  6. Novartis Pharmaceuticals Corporation $377 19 payments
  7. Grifols USA, LLC $366 22 payments
  8. United Therapeutics Corporation $336 17 payments
  9. Regeneron Healthcare Solutions, Inc. $288 11 payments
  10. Genentech USA, Inc. $270 12 payments
  11. Other $2,060 106 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,288 502 payments
  2. Education $187 3 payments
Products named General payments · program years 2019–2025
  1. UPTRAVI $945 42 payments
  2. OPSUMIT $704 32 payments
  3. TRELEGY ELLIPTA $634 65 payments
  4. OFEV $517 31 payments
  5. SPIRIVA RESPIMAT $481 26 payments
  6. Adempas $452 26 payments
  7. Prolastin-C Liquid $366 22 payments
  8. XOLAIR $340 17 payments
  9. DUPIXENT $288 11 payments
  10. BREZTRI $265 16 payments
  11. Other $4,409 268 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

505 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record